Loading…

Exelixis, Inc.EXELCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Oncology biotech built around Cabometyx (cabozantinib) for kidney and other cancers.

Momentum leader 92
Mkt cap
$16.7B
US dollars, full cap
Free float
97%
of shares outstanding
$/day
$202M
20-day average traded
Fwd P/E
17.7×
forward earnings
ROIC−WACC
+64.5 pp
WACC 7.3%
Hurdle
-22 pp
Req g minus delivered
Next earnings
83 days
9 Feb 2027
Close · USD$68.29
1D-0.3%
1W-3.4%
1M+6.1%
3M+27.2%
6M+36.9%
YTD+55.8%
1Y+61.0%
ATR %3.2%
Beta0.64
52w lowhigh7.3% off high

What Exelixis does

Oncology biotech built around Cabometyx (cabozantinib) for kidney and other cancers.

Sells Cabometyx itself in the US through specialty pharmacies, and earns royalties and milestone payments from partners Ipsen and Takeda, who sell it in Europe and Japan. Each new approved use extends the number of patients who can receive it.

Products and services

  • Cabometyx (cabozantinib)
  • Cometriq
  • Oncology combination pipeline

Customers

  • Oncologists
  • Health systems
  • Payers

Where it sits in the supply chain

  • Pharmaceuticals
  • Biotech
  • Oncology - kidney/liver/thyroid cancer

What could go right

  • Cabometyx label expansion into new cancer types
  • International royalty growth via partners

What could go wrong

  • Heavy revenue reliance on a single drug franchise
  • New immuno-oncology combinations from rivals

Moat: narrow (IP / patents, installed base). Cabometyx's established efficacy and combination use with immunotherapy anchor a loyal oncology prescriber base.

Headquarters: Alameda, California, United States · Founded: 1994 · Employees: 1,077

Named competitors

Exelixis at a glance

Size Exelixis (EXEL) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $16.7B, the 553rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $68.29 on 18 Nov 2026.

Performance Over six months the shares gained 36.9%, against +4.4% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.

Growth Revenue grew 9.1% over the last twelve months (peer median +23.5%); the operating margin is 40.2% (peer median 20.8%).

Valuation It trades at 17.7× forward earnings against a peer median of 24.1× (7th cheapest of 20).

Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -22 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 64.5 points above its cost of capital (7.3% WACC).

Short interest Short interest is 10.5% of the free float (30 Oct 2026).

Next results Next results expected around 9 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026EXEL 138Peer median 105
Six months, rebased to 100: Exelixis against the median of its 20 peers (local-currency closes).

Exelixis financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$2.50B$2.32B$2.17B$1.83B$1.61B
Revenue growth—+7%+18%+14%—
Gross profit$2.40B$2.24B$2.09B$1.76B$1.55B
EBITDA$1.03B$922M$719M$197M$222M
Net income$885M$783M$521M$208M$182M
Free cash flow$1.16B$876M$672M$293M$335M
Capital expenditure$12.0M$8.43M$28.4M$40.5M$27.7M
Total debt$162M$201M$216M$216M$208M

Quarterly statements and history in the cockpit →

Exelixis competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%-10%0%+10%ASNDSOBIJAZZ4507ORNAV6446000538688506TORNTPHARM1801ALNYLAURUSLABS6990ZYDUSLIFEDRREDDYSIG1177RECVTRSEXEL6-month return →1-month return →
Up and to the right = strong over both horizons. Exelixis is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%+200%0×500×1,000×ASNDSOBIJAZZ45076446TORNTPHARM18016990SIGEXELRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Exelixis is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%+150%0%50%100%150%ASNDSOBIJAZZ6446TORNTPHARM1801ALNYLAURUSLABS6990DRREDDYVTRSEXELGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Exelixis is the large dot.

Exelixis competitors and peer comparison

Head to head with its named competitors (EXEL vs BMY vs MRK vs 4523.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Exelixis EXEL$16.7B+37%+9%40%17.7×-3.8%
Bristol Myers Squibb BMY$122B+3%+4%33%9.2×-13.1%
Merck & MRK$340B+23%+5%18%16.4×8.3%
Eisai 4523.T$9.36B+11%+11%6%26.6×10.7%

How Exelixis compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Exelixis against its 20 peers (data as of 18 Nov 2026)
MeasureEXELPeer medianRank in peer set
1-month return+6.1%+5.8%11th highest of 21
6-month return+36.9%+4.4%4th highest of 21
Distance from 52-week high-7.3%-6.8%10th lowest of 21
Revenue growth (TTM)+9.1%+23.5%5th lowest of 21
Operating margin40.2%20.8%2nd highest of 21
Forward P/E17.7×24.1×7th cheapest of 20
Growth the price implies (Req g, 7 yrs)-3.8%6.2%4th least demanding of 19
Growth delivered (Del g)+18.6%+12.3%7th highest of 19
Hurdle (Req g minus delivered)-22.4 pp-11.2 pp4th least demanding of 19
ROIC minus cost of capital+64.5 pp+7.2 pphighest of 21
EV / EBITDA15.4×18.2×8th cheapest of 18
Net debt / EBITDA-0.7×1.1×5th least indebted of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Exelixis EXELUnited States$16.7B+37%+9%40%17.7×-3.8%+18.6%
Ascendis Pharma A/S ASNDUnited States$16.9B+12%+94%18%28.0×19.2%+152.4%
Swedish Orphan Biovitrum SOBI.STSweden$16.1B+6%+15%30%24.1×-2.1%+13.1%
Jazz Pharmaceuticals Public JAZZUnited States$15.9B+4%+13%25%9.3×-2.8%+12.5%
Shionogi & 4507.TJapan$17.6B+3%+46%29%11.8×0.2%+11.0%
Orion ORNAV.HEFinland$15.7B+41%+34%38%23.6×-6.2%+11.7%
PharmaEssentia 6446.TWTaiwan$15.0B+67%+78%40%31.9×23.7%+94.8%
Yunnan Baiyao 000538.SZChina$15.0B+11%+5%11%18.3×-0.2%+4.7%
Sichuan Biokin Pharmaceutical 688506.SSChina$14.9B-7%+14%-43%n/an/an/a
Ipsen IPN.PAFrance$14.8B+1%+14%30%10.8×-6.7%+7.2%
Torrent Pharmaceuticals TORNTPHARM.NSIndia$18.8B+3%+42%22%70.2×37.6%+11.3%
Innovent Biologics 1801.HKHong Kong$18.9B+4%+43%17%52.3×11.6%+26.8%
Alnylam Pharmaceuticals ALNYUnited States$20.0B-50%+56%20%21.2×0.5%+49.8%
Laurus Labs LAURUSLABS.NSIndia$13.4B+73%+23%24%76.4×51.2%+7.3%
Sichuan Kelun-Biotech Biopharmaceutical 6990.HKHong Kong$13.0B-1%+44%-38%1,176.1×55.3%+33.6%
Zydus Lifesciences ZYDUSLIFE.NSIndia$12.8B+18%+24%17%30.0×n/an/a
Dr. Reddy's Laboratories DRREDDY.NSIndia$12.5B+5%-4%9%32.0×30.7%+12.1%
Sigma Healthcare SIG.AXAustralia$22.4B+2%+209%9%38.4×28.9%+26.1%
Sbp 1177.HKHong Kong$12.2B+5%+15%30%17.5×-5.7%+5.4%
Recordati REC.MIItaly$12.0B+3%+8%30%16.6×1.1%+12.6%
Viatris VTRSUnited States$23.3B+23%+5%11%7.5×11.2%+3.7%

Questions

Who are Exelixis's main competitors?
Named competitors: Bristol Myers Squibb (BMY), Merck (MRK), Eisai (4523.T). The cockpit's measured peer set (industry) also includes Ascendis Pharma A/S (ASND), Swedish Orphan Biovitrum (SOBI.ST), Jazz Pharmaceuticals Public (JAZZ), Shionogi & (4507.T), Orion (ORNAV.HE), PharmaEssentia (6446.TW).
Is Exelixis expensive compared with its peers?
On forward p/e it trades at 17.7× against a peer median of 24.1×, 7th cheapest of 20 in its peer set. For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -22 pp: the price already allows for a slowdown.
How has Exelixis stock performed?
Over six months to 18 Nov 2026 the shares returned +36.9% against +4.4% for the median peer; over one year +61.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.